Association of aberrant methylation at promoter regions of tumor suppressor genes with placental pathologies. (June 2016)

• Record Type: Journal Article
• Authors: Rahat, Beenish; Thakur, Shilpa; Hamid, Abid; Bagga, Rashmi; Kaur, Jyotdeep
• Is Part Of: Epigenomics. Volume 8:Number 6(2016)
• Page Start: 767
• Page End: 787
• Publication Date: 2016-06
• Subjects: APC -- DNA methylation -- GTDs -- histone modifications -- P16 -- PE -- placenta -- PRKCDBP -- RASSF1A -- RB1; Epigenesis -- Periodicals; Genomics -- Periodicals; Chromatin -- Periodicals; DNA -- Periodicals; 572.87
• DOI: 10.2217/epi.16.7
• Languages: English
• ISSNs: 1750-1911

Abstract

Aim: The resemblance between invasive behavior of cancer cells and placental trophoblasts and the role of aberrant epigenetic regulation in cancer development is well known.Methods: We analyzed the role of promoter region CpG-methylation and H3K9/27me3 of tumor suppressor genes in normal and pathological pregnancies and utilized their CpG-methylation data to search for fetal DNA epigenetic marker in maternal blood.Results: CpG and H3K9/27-methylation associated decreased expression of RASSF1A and APC and increased expression of P16, RB1 and PRKCDBP was observed with advancing normal gestation. Gestational trophoblastic diseases and preeclampsia revealed gene-specific epigenetic deregulation of candidate tumor suppressor genes. Furthermore, APC and PRKCDBP showed the potential to act as fetal DNA epigenetic markers, similar to RASSF1A .Conclusion: Deregulation of methylation of tumor suppressor genes contributes to the development of preeclampsia and gestational trophoblastic diseases. APC and PRKCDBP may act as fetal DNA epigenetic markers for prenatal diagnosis.